Oncotarget will begin publishing two issues a week, providing even more ground-breaking research to its readers

Oncotarget is a peer-reviewed journal published by Impact Journals and available to the public through open access. The journal was established 2010, publishing a single issue every month. To provide oncology researchers a forum to rapidly publish important or timely research, the journal increased its publishing frequency to every week. On the home page of the journal’s website, the publisher states that rising importance, impact, volume and quality have prompted the journal to soon increase its publishing frequency again to twice a week, every Tuesday and Friday and Oncotarget’s lacrosse camp . This rapid publication schedule is possible because as soon as papers are accepted for publication by Oncotarget they are included directly to final paginated issues that are released to PubMed quickly and in their permanent form and learn more about Onctarget. While Oncotarget has been implementing new procedures to streamline the publication process for researchers, they have not lost sight of the most important measure of a journal among researchers deciding where to publish their latest data, impact factor. For 2016 – 2017, Oncotarget has earned a favorable impact factor of 5.168, in-line with the journal’s historic impact factor and more information click here. Now that Oncotarget has further improved its publication process, researchers and readers alike can except to see even more high impact research by some of science’s most influential figures in the pages of the journal. This can be observed in the current issue of Oncotarget, published September 15, 2017, number 40 of volume 8, featuring an image taken from a priority research paper by first author Nikolas K. Finnberg with corresponding author Wafik S. El-Deiry, both of the Department of Hematology/Oncology and Molecular Therapeutics Program of the Fox Chase Cancer Center in Philadelphia, PA, titled “Assessment of CRC patient tumoroid responses to cytotoxic drugs in vitro at 2 weeks following tumor resection”. This paper demonstrates the authors work observing how peripherally and tumor-derived immune cells from patients with colorectal cancer (CRC) respond to various therapeutic drugs using 3D-tumoroids and tumor slice in vitro culture systems. Similar ground-breaking research will now be available twice a week from Oncotarget and read full article.

More Visit: https://www.linkedin.com/company/oncotarget

Leave a Reply

Your email address will not be published. Required fields are marked *